[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Calgary\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":698},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,140,0,25,[9,53,82,106,147,186,208,242,266,294,322,342,366,389,422,452,471,496,525,558,583,606,629,648,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100652223","continuous-interscalene-blocks-and-rebound-pain-100652223",false,"NCT07770165","Continuous Interscalene Blocks and Rebound Pain","Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial","Inclusion Criteria:\n\n* Adults aged \\>18 years of age\n* ASA I-III\n* Scheduled for elective ambulatory total shoulder arthroplasty.\n\nExclusion Criteria:\n\n* ASA IV\n* Revision surgery\n* Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)\n* Preoperative chronic pain or opioid use\n* Preoperative drug dependency\n* Severe respiratory disease or contralateral diaphragmatic paralysis\n* Patient refusal.","ALL","18 Years",{"count":20,"type":21},154,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.\n\nRebound pain has been defined in some studies as the \"the transition from well-controlled pain (numerical rating scale \\[NRS\\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance.\"",[27,28,29,30,31,32,33,34],"Total Shoulder Arthroplasty","Reverse Total Shoulder Arthroplasty","Interscalene Analgesia","Interscalene Blocks","Interscalene Nerve Block","Orthopedic Surgery Patients","Locoregional Anaesthesia","Rebound Pain",[36,37,38,39,27,28,34],"Interscalene","Nerve Block","Catheter","Continuous Interscalene Block","NOT_YET_RECRUITING","2026-08-17",{"date":43,"type":44},"2026-08-19","ACTUAL",{"date":46,"type":21},"2026-10",{"date":48,"type":21},"2027-05",{"name":50,"class":51},"University of Calgary","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100652300","neuromodulation-during-the-prodrome-to-prevent-disabling-migraine-attacks-in-youth-100652300","NCT07772427","Neuromodulation During the Prodrome to Prevent Disabling Migraine Attacks in Youth","Neuromodulation During the Prodrome to Prevent Disabling Migraine Attacks in Children and Adolescents - a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* youth aged 8-\\\u003C18 years with a diagnosis of migraine using gold standard International Classification of Headache Disorders criteria\n* self-reporting 2-14 headache days\u002Fmonth in the last 3 months\n* reporting prodromal symptoms that predict a headache within six hours \\>75% of the time.\n\nTo proceed past the 60-day screening period to randomization, participants will need to report 3-28 qualifying prodrome events with \\>75% of these events followed by a headache within 6 hours.\n\nExclusion Criteria:\n\n* the inability to read or understand English\n* a diagnosis of psychosis, schizophrenia, or moderate-severe autism, moderate-severe developmental delay or moderate-severe intellectual disability\n* implanted electrical device\n* uncontrolled epilepsy (i.e., \\>2 seizures in the past year)\n* abnormal skin on both upper arms\n* arm circumference \\\u003C20 cm\n* severe cardiac or cerebrovascular disease\n* prior participation in the trial","8 Years",{"count":62,"type":21},30,[24],"Background \\& Rationale:\n\nOne in ten Canadian youth have migraine, a disabling neurological disease that is more common in females and characterized by moderate-severe disabling headaches. Migraine attacks occur in a cycle that begins with a prodromal phase, followed by aura, a pain phase (headache), and finally a postdrome phase when the pain is resolved but other symptoms persist. The prodrome is recognized by \\~90% of all youth with migraine, occurs up to 24 hours before headache onset, and consists of a variety of symptoms including, but not limited to, food cravings, fatigue, yawning, mood changes, and sensory hypersensitivity (e.g., light sensitivity). Prodromal symptoms are disabling and frequently graded as moderate to severe. All acute migraine treatments for youth have been studied for use in the pain phase, with the greatest treatment success early in this phase. Unfortunately, only \\~1\u002F3 of youth achieve pain freedom within two hours. Recently, a groundbreaking trial found that treatment during the prodrome could prevent the pain phase, although prodromal treatment does not exist for youth.\n\nIn considering the most innovative, safe, and patient-centered prodromal intervention, remote electrical neuromodulation (REN) is the obvious choice. The investigator's engagement with 175 youth with migraine and their caregivers shows that REN is preferred when pill-based interventions are ineffective or impractical. REN has none of the limitations of pill-based prodromal treatment. The REN device is wearable, battery-operated, worn on the upper arm, and controlled wirelessly by a smartphone application. REN electrically stimulates sensory nerves in the arm below their perceived pain thresholds, but above their depolarization thresholds, to induce a conditioned pain modulation response in the brain to modulate incoming migraine pain signals.\n\nClinical trial and observational studies in youth with migraine have shown REN's safety and efficacy for home-based treatment during the pain phase and led the FDA to clear its use in youth \\>8 years. In the adolescent trial, 71% of participants had pain relief at two hours, there were no serious adverse events (AE), and only one device-related AE (transient arm pain) occurred. Also, emerging data show that adults with migraine in the prodrome phase display pain facilitation due to a deficit in pain modulation. Thus, REN's mechanism of action is likely to be more effective during the prodrome vs. the pain phase as it can \"turn on\" deficient pain modulatory areas earlier when they are most impaired.\n\nResearch Question \\& Objectives:\n\nThe investigators aim to determine the feasibility of implementing REN treatment during the prodrome to prevent migraine pain in youth with migraine, and hypothesize that:\n\n1. trial design will be feasible\n2. REN will be feasible for prodromal treatment, with \\>80% of participants using their assigned device to treat a qualifying prodrome.\n\nThe following feasibility and acceptability outcomes will be measured:\n\n1. proportion of eligible youth that are enrolled into the screening period, subsequently randomized, and treat a qualifying prodrome with REN.\n2. recruitment rate, retention, and withdrawals.\n3. participant feedback.\n\nAll secondary outcomes will be reported descriptively, and adverse events will be recorded and reported.\n\nMethods:\n\nThis study will be a pilot randomized, single centre, double-blind, parallel group, sham-controlled trial comparing active to sham REN for the prevention of headache within 24 hours of treating prodromal symptoms in youth with migraine. Participants will be recruited from headache and neurology clinics at the Alberta Children's Hospital.\n\nEligible and consenting participants will complete an intake visit and enter a 60-day screening period where they will complete electronic daily diaries to determine prodrome or headache occurrence and features. Participants with 3-28 qualifying prodromes during screening, where \\>75% are followed by a headache within 6 hours, will be randomized 1:1 to treat one qualifying prodrome with active or sham REN over a 60-day treatment period. Participants will be trained on device use and will be instructed to not use any co-interventions during the qualifying prodrome; if headache onsets after the prodrome, participants will be instructed to use their typical acute treatment. During the treated prodrome, a survey will determine the presence, type, and number of prodromal symptoms. Surveys at 2, 24, and 48 hours post-treatment will record the presence or absence of headache, its characteristics, and AEs.\n\nThe randomization sequence will be prepared by a biostatistician and will follow randomly ordered blocks of four and six, with variable block sizes. Only research pharmacists will have access to this sequence to prepare consecutively numbered blinded and matched study kits. These kits will contain a restricted mobile phone with only the REN software application pre-installed.",[66,67],"Migraine","Migraine Headache",[69,70,71,72,73,74,75],"pediatric","migraine","headache","neuromodulation","prodrome","treatment","REN","2026-08-15",{"date":43,"type":44},{"date":46,"type":21},{"date":80,"type":21},"2028-09",{"name":50,"class":51},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":52},"100651744","phase-4-reliability-of-expired-allergens-in-patch-testing-a-comparative-study-with-non-expired-series-100651744","NCT07765563","Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series","Inclusion Criteria:\n\n* Adults (age 18 years or older) referred for patch testing.\n\nExclusion Criteria:\n\n* Relative or absolute contraindication to patch testing\n* Wide spread dermatitis prior to patch placement\n* Inability to return to clinic for reading of results\n* Patient non-consenting",{"count":89,"type":21},100,[91],"PHASE4","Patch testing remains the gold standard in the diagnosis of allergic contact dermatitis. Patches used in testing consist of a wide spectrum of allergens, with variability in the stability of products over time. Due to limited allergen stability, careful storage and preparation is needed to prevent product degradation over time. Expiration dates are provided by manufacturers to ensure stability and reactivity, while minimizing the risk of product degradation contributing to inaccurate testing results. Preparation of patch series can be time intensive and procurement of allergens comes with an associated economic burden. Expired allergens are not routinely used in patch testing, however many clinics have expired allergens accessible. There is paucity of evidence comparing the reactivity of expired vs non-expired patch series. If expired allergens remain effective, this could result in significant cost-savings and accessibility implications for dermatology practice.",[94],"Allergic Contact Dermatitis",[96,97],"contact dermatitis","patch testing","2026-08-10",{"date":100,"type":44},"2026-08-14",{"date":102,"type":21},"2026-09",{"date":104,"type":21},"2027-12",{"name":50,"class":51},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":115,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":52},"100650932","a-clinical-trial-evaluating-fecal-microbiota-transplantation-fmt-in-adolescents-with-adhd-100650932","NCT07756255","A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD","Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)","FMT-ADHD-2026","Inclusion Criteria:\n\n1. Between 13-17 years of age with consent of a legal guardian: Participants should be at least 13 years old and not older than 17 years at the day of screening (V1).\n2. Have a primary diagnosis of ADHD as confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).\n3. Be on a stable appropriate dose of an appropriate first-line pharmacological treatment for at least 8 weeks prior to the day of screening (V1).\n\n   a. First line pharmacotherapy treatment will be defined based on the CADDRA guidelines \\[63\\] and include the following\n\n   Amphetamine-based psychostimulants:\n\n   i. Mixed amphetamine salts (amphetamine and dextroamphetamine) ii. Lisdexamfetamine dimesylate\n\n   Methylphenidate-based psychostimulants:\n\n   i. Methylphenidate hydrochloride, Methylphenidate hydrochloride (extended release, multilayer release capsules) ii. Methylphenidate hydrochloride (extended release, OROS tablets) iii. Methylphenidate hydrochloride (controlled release, multi-layer beat capsules) iv. Methylphenidate hydrochloride (extended-release oral suspension)\n4. Have a score of ≥ 18 on the inattention subset (questions 1-9) and\u002For the hyperactivity\u002Fimpulsivity subset (questions 10-18) of the SNAP-IV 26-Item Parent Rating Scale on the day of screening (V1) and the baseline visit (V2).\n5. Able to communicate and complete study assessments in English.\n6. Able to comply with all protocol procedures.\n7. Consenting guardian\n\nExclusion Criteria:\n\n1. Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria for the following conditions according to the MINI-KID:\n\n   1. Diagnosis of a Substance Use Disorder within the last 3 months prior to screening. \\*(Criteria should include Alcohol and Non-Alcohol substances except Cannabis)\n   2. Moderate or severe Substance Use Disorder for Cannabis use in the last 3 months\n   3. Currently active high suicidality. Eligibility of Participants who meet criteria for moderate suicidality is determined by clinical judgment of Principal Investigator.\n   4. Active Anorexia Nervosa or Bulimia Nervosa in the last 3 months.\n   5. Tic Disorders\n   6. Psychosis\n   7. Obsessive Compulsive Disorder\n   8. Bipolar Disorder\n   9. Conduct Disorder\n2. Participant has a score of ≥ 8 on the oppositional defiant subset of the SNAP-IV 26-Item Parent Rating Scale (questions 19-26) on the day of screening (V1).\n3. Intellectual or learning disability based on previous documented diagnosis or clinical judgment of Principal Investigator.\n4. Documented diagnosis of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS).\n5. Documented diagnosis of schizophrenia or schizoaffective disorder.\n6. Documented diagnosis of Autism Spectrum Disorder (ASD) or currently undergoing assessment for suspected ASD.\n7. Use of systemic antibiotics for medical purposes within the last 3 months prior to the day of screening (V1).\n8. Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months prior to the day of screening (V1).\n\n   a) Eligibility and required washout period of participants with use of over-the-counter prebiotics or probiotics will be determined by clinical judgment of Principal Investigator.\n9. Use of experimental drugs in the last 3 months prior to the day of screening (V1).\n10. Documented clinical diagnosis of inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, and\u002For celiac disease.\n11. Documented diagnosis of conditions causing immunosuppression and\u002For currently receiving immunosuppressive treatments.\n12. Documented clinical diagnosis of significant bleeding disorders.\n13. History of oropharyngeal dysphagia or other swallowing disorder, and\u002For self or study partner reported difficulty with taking oral capsules or pills.\n14. Breastfeeding, pregnant or seeking to get pregnant during the course of this study. Female participants of childbearing age should be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, barrier contraceptives, sexual abstinence, or a vasectomized partner) for the duration of their participation in the trial.\n15. Participants who are currently hospitalized or institutionalized.\n16. Reported allergy to Vancomycin or Nitazoxanide\n17. Hepatic dysfunction:\n\nA) Documented history or current diagnosis of an acute or chronic hepatic disease (e.g., cirrhosis, hepatitis, hepatic impairment) OR\n\nB) Abnormal - Liver Function Tests (LFTs): Screening laboratory results indicating clinically significant hepatic dysfunction:\n\n* Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥3 the Upper Normal Limit (UNL)\n* Total Bilirubin \\> 1.5 × ULN (except in cases of documented Gilbert's Syndrome) 19. Renal dysfunction: A) Diagnosed Renal Disease: Any documented medical history or current diagnosis of kidney disease, acute kidney injury, or other clinically significant renal impairment. OR B) Abnormal Renal Function Tests: Screening laboratory results indicating significant renal dysfunction. Creatinine \\> 1.5 × ULN\\*\n\n  * Potential participants presenting with mild, non-clinically significant laboratory abnormalities (e.g., AST\u002FALT between 1.0 and 3.0 × ULN, or isolated borderline creatinine variations confirmation of enrollment into the study will be dependent of the study physician.",true,"13 Years",{"count":117,"type":21},64,[119],"PHASE2","The primary goals of this phase 2 clinical trial are to determine the feasibility, safety, and tolerability of oral Fecal Microbiota Transplantation (FMT) in adolescents (aged 13-17) with Attention-Deficit\u002FHyperactivity Disorder (ADHD).",[122,123,124],"ADHD","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD - Combined Type",[126,127,128,129,130,131,132,133,122,134,135,136,137,138,139],"microbiome","microbiota transplants","fecal microbiota transplantation","gut microbiome therapy","gut microbiome","gut microbiota","neurodevelopmental disorders","neurodevelopment","Attention Deficit Hyperactivity Disorder","gut brain axis","FMT","adolescent psychiatry","psychiatry","neuroscience","2026-08-05",{"date":98,"type":44},{"date":143,"type":21},"2026-08-31",{"date":145,"type":21},"2029-08-31",{"name":50,"class":51},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":154,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":159,"conditions":160,"keywords":165,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},"100554114","phase-3-the-partum-trial-postpartum-aspirin-to-reduce-thromboembolism-undue-morbidity-100554114","NCT06494878","The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial","Inclusion Criteria:\n\n* ONE (or more) First Order Criterion:\n\n  1. Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE:\n\n     i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and\u002For\n  2. Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND\u002FOR\n\nTWO (or more) Second Order Criteria:\n\n1. Pre-pregnancy BMI ≥30 kg\u002Fm²\n2. Smoking in the current pregnancy or within 3 months prior to pregnancy\n3. Previous clinical history of superficial vein thrombosis\n4. Preeclampsia\n5. Current pregnancy ending in stillbirth (pregnancy loss \\>20 weeks gestation)\n6. Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery)\n7. Small-for-gestational-age infant at time of delivery (\\\u003C3rd percentile adjusted for gestational age and sex)\n8. Peripartum or postpartum infection (symptoms\u002Fsigns of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs)\n9. Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode)\n\nExclusion Criteria:\n\n1. More than 48 hours since delivery at the time of randomization\n2. Received more than 1 dose of LMWH since delivery\n3. Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and\u002For local investigator. May include but is not limited to:\n\n   1. Documented history of provoked or unprovoked VTE\n   2. Mechanical heart valve(s)\n   3. Known antiphospholipid syndrome (APS)\n   4. Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency\n4. Need for postpartum ASA as judged by their physician and\u002For local investigator. May include but is not limited to:\n\n   1. Documented history of myocardial infarction\n   2. Documented history of ischemic stroke or transient ischemic attack (TIA)\n5. Active bleeding, excluding normal vaginal bleeding, at the time of randomization\n6. Known medical condition as judged by their physician and\u002For local investigator to be a contraindication to ASA or LMWH including known ASA or LMWH allergy\n7. \\\u003C18 years of age\n8. Unable or declined consent","FEMALE",{"count":156,"type":21},8805,[158],"PHASE3","The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.",[161,162,163,164],"Venous Thromboembolism","Postpartum Period","Aspirin","Low Molecular Weight Heparin",[166,167,168,169,170,171,172,173,174,175],"deep vein thrombosis","pulmonary embolism","postpartum","pregnancy","thrombophilia","cesarean delivery","preeclampsia","small-for-gestational age infant","postpartum hemorrhage","postpartum infection","RECRUITING","2026-07-23",{"date":179,"type":44},"2026-07-27",{"date":181,"type":44},"2026-06-04",{"date":183,"type":21},"2030-12",{"name":50,"class":51},12,{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100645846","phase-1-transcranial-ultrasound-stimulation-for-tourette-syndrome-100645846","NCT07699783","Transcranial Ultrasound Stimulation for Tourette Syndrome","TUS-TS","Inclusion Criteria:\n\n* Diagnosis of Tourette Syndrome according to DSM-5 criteria\n* a total motor or vocal tic severity sub-score of at least 15, or a total tic severity score greater than 22 on the Yale Global Tic Severity Rating Scale (YGTSS)\n* a stable medication regimen during the 3 months prior, clinically stable in any psychiatric comorbidities\n\nExclusion Criteria:\n\n* Contraindications for MRI",{"count":194,"type":21},20,[196],"PHASE1","This is a phase 1 clinical trial investigating the use of low-energy Transcranial Ultrasound Stimulation (TUS) to treat Tourette Syndrome (TS).\n\nObjectives and Background. TS is a neurodevelopmental condition marked by motor and vocal tics that often resist standard pharmacological or behavioral treatments. Current neuromodulation options like Deep Brain Stimulation (DBS) are invasive, while non-invasive methods like TMS lack the precision to reach deep brain structures.\n\nThe study aims to:\n\n1. Evaluate tolerability: Assess TUS safety in older adolescents and adults with TS.\n2. Test efficacy: Compare TUS at the intralaminar thalamic nuclei (CM\u002FPf\u002FVoi) and the supplementary motor area (SMA) against a sham treatment to see if it reduces tic frequency and severity.\n3. Optimize protocols: Determine if dual-target or multiple-session stimulation is more effective than single-target or single-session protocols.\n\nTUS uses low energy, pulsed, focused ultrasound to induce transient neuromodulatory responses lasting up to 60 minutes. TUS can precisely target deep structures like the thalamus.\n\nStudy Methods\n\n* Design: A phase 1, double-blind, crossover trial.\n* Participants: 20 individuals (ages 16+) with a diagnosis of TS and significant tic severity (YGTSS score \\> 22 or sub-score \\> 15).\n* Procedure: Participants receive four different modalities over four separate weeks, with 7-day washouts:\n\n  * TUS of the CM\u002FPf\u002FVoi only.\n  * TUS of the SMA only.\n  * Combined TUS of both targets.\n  * Sham TUS.\n* Evaluation: The primary endpoint is the percent change on the Rush Video-Based Tic Rating Scale (RVBTRS). Secondary measures include the Yale Global Tic Severity Scale (YGTSS) and the Premonitory Urges for Tics Scale (PUTS).\n\nBecause TUS requires extreme precision to hit deep brain targets, every participant undergoes a comprehensive imaging protocol using a 3T GE UHP scanner.\n\n* Mapping the Targets: We use Diffusion Tensor Imaging (DTI) and Tractography to locate the specific \"wiring\" of the individual's brain. This allows to find:\n\n  * The CM\u002FPf\u002FVoi (Centromedian-parafascicular complex) in the thalamus.\n  * The SMA (Supplementary Motor Area) in the cortex.\n* Precision Imaging: High-resolution 1 mm-isotropic T1-weighted, T2-weighted, and Zero Echo Time (ZTE) images are used. ZTE is particularly important as it helps the BabelBrain software account for the thickness and density of the skull, which can deflect ultrasound waves.\n* Real-Time Tracking: During the actual stimulation, the team uses a Brainsight neuro-navigation system. This acts like a GPS, using the patient's MRI \"map\" to ensure the ultrasound transducer is perfectly aligned with the target.\n\nInnovation This is the first human study to apply TUS to TS patients. By targeting both deep and cortical regions independently or simultaneously, the researchers aim to modulate the \"network-level\" connectivity implicated in tic generation.\n\nTechnical Ultrasound Parameters The study uses a custom 128-element phased-array transducer (Sonic Concepts H317) to deliver TUS.\n\n* Core Settings:\n\n  * Frequency: 250 kHz.\n  * Intensity: spatial-peak pulse-average intensity (ISPPA) of 10 W\u002Fcm2\n* Targeting \\& Safety:\n\n  * BabelBrain Software: Calculates real-time acoustic simulations to correct for bone aberrations and ensure the Mechanical Index (MI) stays below 1.9 and thermal rise remains under 2°C.\n  * Electronic Steering: Allows the focal spot to be moved without physically repositioning the device, enabling coverage of large areas like the SMA or deep structures like the CM\u002FPf\u002FVoi complex.\n* Biological Protocols:\n\n  * Inhibitory: pulse repetition frequency (PRF), 10% duty cycle, lasting 120 seconds.\n  * Excitatory: \"theta burst\" PRF, 10% duty cycle, lasting 80 seconds. Clinical Assessment Criteria\n\nThe trial employs three main scales to capture both objective tic data and subjective patient experiences:\n\n1. Rush Video-Based Tic Rating Scale (RVBTRS):\n\n   * The Primary Measure: This is the only validated tool that provides an objective assessment by analyzing 10-minute video recordings.\n   * Method: Two blinded evaluators count tics and rate their severity across two views: a close-up (head\u002Fshoulders) and a full-body frontal view.\n   * Focus: It specifically measures the patient's ability to actively inhibit tics during the recording.\n2. Yale Global Tic Severity Scale (YGTSS):\n\n   * The Gold Standard: A clinician-rated interview that assesses symptoms over the prior 7-10 days.\n   * Scoring: It rates motor and phonic tics separately on five dimensions: number, frequency, intensity, complexity, and interference.\n   * Baseline Requirement: To participate in the trial, patients must have a total tic severity score of at least 22 (or a sub-score of 15).\n3. Premonitory Urges for Tics Scale (PUTS):\n\n   * Self-Report: A 9-item questionnaire where patients rate the intensity of pre-tic sensations (like pressure, itchiness, or tension) on a scale of 1 to 4.\n   * Interpretation: Scores range from 9 to 36; higher scores reflect more distressing urges.",[199],"Tourette Syndrome","2026-07-09",{"date":202,"type":44},"2026-07-13",{"date":204,"type":21},"2026-08-01",{"date":206,"type":21},"2028-06-01",{"name":50,"class":51},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100646679","phase-3-act-global-ia-thrombolysisact-react-004domain-within-the-act-global-adaptive-platform-trial-nct06352632-100646679","NCT07687056","ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","A Multicentre,Prospective,Randomized,Open Label,Blinded-endpoint Trial for Reperfusion Enhancement After Completing Thrombectomy Using Intraarterial Thrombolysis(REACT-IA-Thrombolysis Domain)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke(ACT-GLOBAL) NCT06352632","ACT-REACT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Clinical diagnosis of stroke\n\nExclusion Criteria:\n\nThere are no platform level exclusion criteria.",{"count":217,"type":21},1500,[158],"Study Design and Duration:\n\nThis domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 subjects with Acute Ischemic Stroke (AIS) who undergo EVT. Randomisation will be stratified by country\u002F region, and the IA thrombolytic agent (tenecteplase or alteplase). Minimal sufficient balance algorithm will operate within each stratum to preserve balance on key covariates while maintaining allocation randomness.\n\nParticipants will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. Primary outcome data will be determined by simplified, structured method of assessment using the modified Rankin scale (mRS), conducted through centralized telephone interviews or online media performed by central trial personnel blinded to treatment assignment and received.\n\nDomain Interventions:\n\nThe intervention group will receive a single dose of local intraarterial thrombolysis using either tenecteplase (at a dose of 0.0625mg\u002Fkg; maximum dose of 6.25mg) or alteplase (0.225 mg\u002Fkg; maximum dose, 20mg) at the end of EVT procedure plus standard of care while the control group will receive standard of care alone. The selection of the thrombolytic agent will be determined according to local availability. The dose of intraarterial thrombolysis will be increased if the above dose meets prespecified posterior probabilities at the first or second interims.\n\nIn all eligible patients:\n\n1. Local intra-arterial thrombolysis using either tenecteplase at a dose of 0.0625mg\u002Fkg \"maximum dose of 6.25mg\" or alteplase \"0.225 mg\u002Fkg; maximum dose, 20mg\\*\n2. No intra-arterial thrombolysis.\n\n   * The dose of IA thrombolysis may be doubled to 0.125 mg\u002Fkg tenecteplase or 0.45 mg\u002Fkg alteplase if this dose shows futility at pre-specified interims Randomization will be stratified by country\u002F region, the IA thrombolytic agent used (tenecteplase or alteplase). IA thrombolysis will be administered as a one-time treatment.",[221,222,223],"Stroke, Acute Ischemic","Endovascular Thrombectomy","Acute Ischemic Stroke AIS",[225,226,227,228,222,229,230,231,232],"Tenecteplase","Alteplase","Intra-arterial thrombolysis","Stroke","EVT","Domain","Platform","Thrombolysis","2026-06-29",{"date":235,"type":44},"2026-07-07",{"date":237,"type":21},"2026-06-10",{"date":239,"type":21},"2031-03-31",{"name":50,"class":51},13,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":154,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":52},"100630447","feasibility-of-imaging-breast-implants-with-a-transmission-based-microwave-scanner-100630447","NCT07487792","Feasibility of Imaging Breast Implants With a Transmission-based Microwave Scanner","Feasibility of Imaging Breast Implants With a Transmission-based Transmission Scanner","Inclusion Criteria:\n\n* Women with breast implants placed at least 6 months prior who are asymptomatic for implant rupture as well as those with known implant rupture\n* Female\n* Minimum of 18 years of age\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Women who are currently pregnant or breastfeeding\n* Women with active breast infections\n* Women with nipple piercings (unless removed prior to scanning)\n* Women with implanted electronic device\n* Women with physical limitations that prevent them from placing their breasts inside the scanner",{"count":250,"type":21},10,[24],"The goal of this clinical trial is to assess whether microwave scans can depict the presence of implants in the breast in women with existing breast implants that were surgically placed at least 6 months ago. The main questions it aims to answer are:\n\n1. Can a microwave imaging device effectively scan a breast containing implants?\n2. Can the presence of implants be identified in a microwave scan?\n3. Can the microwave scans of the left and right breasts be compared to assess whether similarity is observed?",[254],"Breast - Female",[256,257],"women","breast implant","2026-06-23",{"date":260,"type":44},"2026-06-25",{"date":262,"type":21},"2026-09-15",{"date":264,"type":21},"2026-12-30",{"name":50,"class":51},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":274,"studyType":275,"phases":4,"briefSummary":276,"conditions":277,"keywords":282,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":52},"100644314","the-prevalence-of-hyperglycemia-in-surgical-patients-with-pre-diabetes-100644314","NCT07662980","The Prevalence of Hyperglycemia in Surgical Patients With Pre-diabetes","Inclusion Criteria:\n\n* Hemoglobin A1c measurement between 6 and 6.4%\n* Scheduled for non-cardiac surgery\n\nExclusion Criteria:\n\n* Age\\>18\n* Pregnancy\n* Any formal diabetes diagnosis\n* Current use of medications that influence blood glucose regardless of the indication\n* Undergoing cardiac, intracranial neurosurgery, bariatric, or pancreatic surgeries",{"count":273,"type":21},750,"30 Days","OBSERVATIONAL","The goal of this study is to measure the prevalence and risks of hyperglycemia in surgical patients with prediabetes. The main questions it aims to answer are:\n\n* What is the prevalence of hyperglycemia in surgical patients with prediabetes?\n* What is the relative risk of postoperative complications associated with hyperglycemia?\n\nTo answer these questions, surgical patients with prediabetes will undergo universal glucose measurement in the perioperative period. Glucose data will be analyzed in conjunction with electronic health record (EHR) data describing patient outcomes.",[278,279,280,281],"Prediabetes or Diabetes","Surgery Complications","Non-Cardiac\u002F Non-Thoracic Surgery","Stress Hyperglycemia",[283,284,285,286],"Prediabetes","Prevalence","Surgical Complications","Perioperative Hyperglycemia","2026-06-17",{"date":258,"type":44},{"date":290,"type":21},"2027-05-01",{"date":292,"type":21},"2028-05-01",{"name":50,"class":51},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":321,"locationsCount":52},"100581690","pharmacogenetic-guided-antidepressant-prescribing-in-adolescents-with-anxiety-and-depression-100581690","NCT06853587","Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression","PGx-GAP","Inclusion Criteria:\n\n* Age 12-17\n* Depression and\u002For anxiety as the primary concern, confirmed by the treating physician\n* Intention to start a new SSRI\n* English fluency\n\nExclusion Criteria:\n\n* Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability\n* History of non-response to 3 or more SSRI medications as confirmed by the treating physician\n* Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate\u002Fchange brain stimulation during study participation\n* History of liver or hematopoietic cell transplant\n* History of CYP2B6, CYP2C19, or CYP2D6 testing","12 Years","17 Years",{"count":304,"type":21},228,[24],"This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and\u002For anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines\u002Frecommendations guided therapy (control intervention).",[308],"Anxiety and Depression",[310,311,312,313,314,315],"depression","anxiety","adolescence","SSRI","antidepressant","pharmacogenetics",{"date":317,"type":44},"2026-06-22",{"date":319,"type":44},"2025-02-11",{"date":104,"type":21},{"name":50,"class":51},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":114,"sex":154,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":52},"100541060","analgesic-efficacy-of-surgeon-administered-transversus-abdominis-plane-blocks-for-caesarean-section-100541060","NCT06324942","Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.","Inclusion Criteria:\n\n* ASA status II to III\n* All patients undergoing elective CS under regional anesthesia at any gestational age.\n\nExclusion Criteria:\n\n* \\- Known drug allergy to local anesthetics\n* Planned general anesthetic\n* NSAID use contraindicated post partum\n* Chronic pain disorder or chronic narcotic use\u002Fdependence\n* Planned vertical abdominal incision\n* Planned Cesarean Hysterectomy.\n* Placenta Previa or suspected Placenta Accreta",{"count":329,"type":21},80,[24],"The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital.",[333,334],"Cesarean Section Complications","Pain, Postoperative",{"date":336,"type":44},"2026-06-15",{"date":338,"type":44},"2025-02-19",{"date":340,"type":21},"2026-12",{"name":50,"class":51},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100642744","early-phase-1-chest-tube-delivered-bupivacaine-to-decrease-postoperative-pain-after-cardiac-surgery-100642744","NCT07643506","Chest Tube-Delivered Bupivacaine to Decrease Postoperative Pain After Cardiac Surgery","A Randomized Double-Blind Placebo Controlled Trial for Chest Tube-Delivered Bupivacaine to Decrease Postoperative Pain After Cardiac Surgery: the FREEZE-B Trial","FREEZE-B","Inclusion Criteria:\n\n* Age 18 years or older at the time of consent\n* Scheduled to undergo elective or semi-elective coronary artery bypass graft (CABG) surgery via midline sternotomy\n* Procedure involves the use of a mammary artery graft\n* Capable of providing informed written consent prior to surgery\n* Able to communicate pain scores using a numeric rating scale (NRS)\n\nThese criteria ensure the study population is the clinically relevant group most likely to benefit from the intervention and that participants can provide valid consent and meaningful pain assessments.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to bupivacaine or any amide-type local anesthetic\n* Emergency or urgent cardiac surgery where obtaining consent prior to the procedure is not feasible\n* Inability to communicate pain using numeric rating scale due to cognitive impairment, language barrier, or altered level of consciousness\n* Participation in another interventional clinical trial that may confound pain outcome\n\nThese exclusion criteria are designed to protect participant safety, ensure the validity and interpretability of study outcomes (pain scoring ability), and maintain scientific rigor.",{"count":351,"type":21},60,[353],"EARLY_PHASE1","Background:\n\nAfter heart surgery, patients require temporary chest tubes - plastic drains placed inside the chest to prevent fluid building up around the heart and lungs. These tubes are often very painful and can limit breathing, coughing, and movement, which necessitates usage of painkiller medication (opioids and non-steroidal anti-inflammatory drugs (NSAIDs)) that have negative side effects and can prolong hospital recovery. Despite this common problem, routine care lacks simple, add-on strategies that directly numb pain at the chest tube sites rather than relying solely on whole-body painkiller medicine.\n\nPurpose:\n\nTo determine whether injecting a long-acting numbing medicine (bupivacaine 0.5%) through chest tubes safely reduces pain and lowers opioid and NSAID use compared with placebo.\n\nObjective:\n\nWith ethics approval, data access, and study procedures already in place before May, the specific objective for this studentship is to collect and analyze data to evaluate the short-term effect of bupivacaine versus placebo on:\n\n* Mean pain scores from initial recovery to chest tube removal\n* Total mean opioid and NSAID use\n\nMethods:\n\nThis single-centre, 1:1 block randomized, double-blind, placebo-controlled trial will enroll 60 adults undergoing coronary artery bypass (procedure to bypass blocked blood vessels supplying heart muscle using healthy blood vessels) at the Foothills Medical Centre. Patients receive either 10 mL bupivacaine 0.5% or normal saline (saltwater placebo) through chest tubes by heart surgeons whenever pain hits ≥3\u002F10 using the Numeric Rating Scale (0 = no pain; 10 = most intense pain), from initial recovery to chest tube removal. Standard pain care will continue for all patients. The study team will record pain scores, opioid and NSAID doses, and any side effects for each group. Interval pain reduction will be measured 30, 60, 120 and 240 minutes post injection. Mean pain reduction and total painkiller use will be compared between the two groups.",[356,357,358],"Coronary Artery Bypass Graft (CABG)","Chest Tubes","Post Operative Pain Control","2026-06-08",{"date":361,"type":44},"2026-06-11",{"date":336,"type":21},{"date":364,"type":21},"2028-06-30",{"name":50,"class":51},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100419996","phase-3-vernakalant-versus-amiodarone-for-post-operative-atrial-fibrillation-in-cardiac-surgery-patients-100419996","NCT04748991","Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","Inclusion Criteria:\n\n1. Age \\>\u002F=18 years\n2. Undergone heart surgery for coronary artery bypass surgery (on-pump or off-pump CABG) and\u002For valve repair or replacement (excluding mechanical valves), including re-operations.\n3. Hemodynamically stable with\u002Fwithout vasopressor support\n\nExclusion Criteria:\n\n1. LVAD insertion or heart transplantation\n2. MAZE procedure\n3. Transcatheter aortic valve replacement (TAVR)\n4. History of or planned mechanical valve replacement\n5. Rheumatic heart disease\n6. Congenital cardiac defect (excluding bicuspid aortic valve or patent foramen ovale)\n7. History of prior atrial fibrillation or flutter\n8. History of ablation for atrial fibrillation\n9. Contraindication to amiodarone\n\n   * PR \\>240ms\n   * Heart block (2nd or 3rd degree)\n   * QTC \\>480ms\n   * Untreated thyroid disorder\n   * AST or ALT \\>2x upper limit of normal\n   * Hepatic cirrhosis\n   * Interstitial lung disease\n10. Received amiodarone within 6 weeks\n11. Contraindications to Vernakalant\n\n    * Known hypersensitivity to Vernakalant\n    * Prolonged QT\n    * Heart block (2nd or 3rd degree)\n    * Use of anti-arrhythmic medication in the past 4 weeks.\n12. Return to OR during CVICU stay or readmission to CIVCU from Cardiac Surgery ward.",{"count":373,"type":21},50,[158],"Post-operative atrial fibrillation is a common problem post cardiac surgery with rates exceeding 30%. Atrial fibrillation has multiple adverse effects on cardiac hemodynamics and can lead to hypotension, diminished end organ perfusion and lengthen the stay in ICU. Amiodarone is the medication of choice used for pharmacological cardioversion and can be used with vasoactive medications. Intravenous amiodarone is associated with hypotension and end organ perfusion requiring escalation in vasoactive support. Vernakalant is novel anti-arrhythmic agent approved in Canada for cardioversion of atrial fibrillation that primarily works on atrial channels and has no effect on contractility or vasodilation. Clinical trials have proved good efficacy of Vernakalant in conversion of paroxysmal atrial fibrillation however there is no comparison of Amiodarone to Vernakalant in post-operative cardiac surgery. We plan to perform a clinical trial comparing Vernakalant to amiodarone in post-cardiac surgery patients with a primary outcome of cardioversion at 90 minutes. Secondary outcomes will follow duration of vasoactive medications, days in ICU and economics.",[377,378],"Atrial Fibrillation","Post-cardiac Surgery",[380,381],"Amiodarone","Vernakalant","2026-06-01",{"date":384,"type":44},"2026-06-03",{"date":102,"type":21},{"date":387,"type":21},"2029-09",{"name":50,"class":51},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":154,"minAge":18,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":52},"100639329","hamstring-strengthening-in-hypermobile-conditions-100639329","NCT07626957","Hamstring Strengthening in Hypermobile Conditions","Effects and Feasibility of Eccentric Hamstring Strengthening in Hypermobility Spectrum Disorders and Hypermobile Ehlers-Danlos Syndrome","Inclusion Criteria:\n\n* Reported diagnosis of HSD or hEDS by a physician\n* Meet the 2017 International Diagnostic Criteria for HSD and hEDS\n* Clearance to participant in exercise participation, determined using the Get Active Questionnaire\n\nExclusion Criteria:\n\n* Other acquired or hereditary connective tissue disorder (i.e., rheumatoid arthritis, Marfan syndrome, etc.)\n* Currently experiencing daily knee pain\n* Prior knee injury or surgery\n* Intra-articular knee injection in the last 12 months\n* Currently pregnant","55 Years",{"count":194,"type":21},[24],"The goal of this clinical trial is to determine how strengthening the hamstring muscles affects the knee joint in people living with hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS). The main questions it aims to answer are:\n\n* Does hamstring strengthening reduce the looseness of the knee joint in HSD\u002FhEDS?\n* Does hamstring strengthening improve clinical outcomes like pain in people living with HSD\u002FhEDS?\n\nParticipants will:\n\n* Attend two exercise classes per week for 12 weeks.\n* Visit the laboratory every 4-6 weeks for testing.",[401,402,403,404],"Hypermobile EDS (hEDS)","Hypermobile Ehlers-Danlos Syndrome","Hypermobile Spectrum Disorder","Hypermobility Type Ehlers-Danlos Syndrome",[406,407,408,409,410,411,412,402,413,414,415],"Exercise","Female","Knee","Joint Laxity","Hypermobility","Joint Stiffness","Ehlers-Danlos Syndrome","Hypermobility Spectrum Disorders","strengthening","eccentric","2026-05-29",{"date":181,"type":44},{"date":382,"type":21},{"date":420,"type":21},"2027-08-01",{"name":50,"class":51},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":114,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":52},"100575181","phase-2-subjective-experience-following-psilocybin-100575181","NCT06768944","Subjective Experience Following Psilocybin","The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults","SEP-1","Inclusion Criteria:\n\n* Individuals of all sexes, gender identities, and ethnicities\n* Ages 18 to 65 years of age at the time of screening\n* Ability to read\u002Fwrite in English\n* Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation\n\nExclusion Criteria:\n\n* Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests\n* Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder\n* Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder\n* Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II\n* Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics\n* Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study\n* Current or recent (within 12 weeks) participation in a clinical trial involving medication administration\n* Cognitive impairment (Folsetin Mini Mental State Exam score \\\u003C 24)\n* A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).\n* Suffered a traumatic brain injury with one of the following symptoms Loss of consciousness \\>30min Alteration of consciousness\u002Fmental state \\>24h Post-traumatic amnesia \\>1 day Glasgow Coma Scale (best available score in first 24 hours) \\\u003C13\n* Any other circumstances that, in the opinion of the investigators, compromises participant safety","65 Years",{"count":432,"type":21},128,[119],"The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of \"magic mushrooms\") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with either a placebo or risperidone, an atypical antipsychotic that block the subjective effects of psilocybin.",[436],"Investigating the Importance of the Subjective Psychedelic Experience",[438,439,440,441,442,443,444],"psychedelics","psilocybin","stress response","cortisol","healthy participants","risperidone","subjective effects",{"date":446,"type":44},"2026-06-02",{"date":448,"type":44},"2026-05-15",{"date":450,"type":21},"2028-01",{"name":50,"class":51},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":4},"100638949","clinical-utility-of-preoperative-thyroid-guidepx-testing-100638949","NCT07584447","Clinical Utility of Preoperative Thyroid GuidePx® Testing","Inclusion Criteria:\n\n* Patients aged 18 years or older at the time of enrollment\n* English-speaking\n* Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)\n* Bethesda III or IV with ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK\n* Tumor 1- 4cm in size\n* No lymph node involvement on ultrasound\n* No gross extrathyroidal extension on ultrasound\n\nExclusion Criteria:\n\n* Prior thyroid operation\n* Distant metastatic disease\n* Personal history of thyroid cancer\n* History of whole-body radiation exposure or radiation to the head and neck region",{"count":459,"type":21},85,"The purpose of this study is to learn whether having Thyroid GuidePx® test results available before treatment may help patients with papillary thyroid cancer and doctors make better-informed treatment decisions.",[462,463],"Papillary Thyroid Cancer","Papillary Thyroid Carcinoma","2026-05-28",{"date":382,"type":44},{"date":467,"type":21},"2026-04",{"date":469,"type":21},"2029-04",{"name":50,"class":51},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":480,"conditions":481,"keywords":487,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":52},"100640196","clinical-information-system-impact-on-hospitalized-patients-with-chronic-disease-100640196","NCT07609381","Clinical Information System Impact on Hospitalized Patients With Chronic Disease","Evaluating the Impact of Alberta Health Services' New Provincial Clinical Information System on Patient Outcomes and Experiences With Chronic Diseases - Study Protocol for a Multi-center Interrupted Time Series Analysis","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of hospital admission.\n* Residents of Alberta eligible to receive acute-care services in AHS facilities.\n* Hospitalized for any cause during the study period (5 years pre-implementation and 2 years post-implementation of the CIS).\n* Meet the validated case definition for one or more of the five key NCDs (diabetes mellitus, chronic kidney disease, coronary artery disease, heart failure, or chronic lung disease) based on ICD codes, laboratory measures, or pharmacy records during standardized lookback periods (up to 5 years for diagnoses; up to 1 year for labs\u002Fpharmacy).\n* Have a qualifying date for the NCD(s) that occurs prior to or during the index hospital admission.\n* Eligible for inclusion in the primary and patient experience outcomes if they survive to hospital discharge.\n* May enter multiple sub-cohorts if more than one NCD is present.\n\nExclusion Criteria:\n\n* Individuals younger than 18 years at the time of hospital admission.\n* Non-residents of Alberta or individuals not eligible for care within AHS facilities.\n* Hospitalizations that end in death (excluded from analyses of the primary outcome and patient experience measures).\n* Patients without evidence of any of the five key NCDs during the lookback period or at the index hospital admission.\n* Admissions outside the study period or admissions for which necessary administrative, laboratory, or pharmacy data are unavailable.",{"count":479,"type":21},124240,"This is a retrospective, observational study using routinely collected information collected by Alberta Health Services. The study will identify patients with chronic disease, defined by one or more of the following conditions; diabetes mellitus, heart failure, coronary artery disease, chronic kidney disease, or chronic lung disease. Adult residents of Alberta with a chronic disease of interest present upon hospital admission and who survive to hospital discharge will be included in the study cohort. The primary outcome will be the composite of hospital readmission or death within 30 days of discharge. Secondary outcomes will include components of the composite, length of stay, patient experiences related to their hospital to home transition of care, and processes of care. Multi-level interrupted time series analysis will be used to compare outcomes before versus after implementation of the Connect Care CIS.",[482,483,484,485,486],"Diabete Mellitus","Kidney Disease","Heart Failure","Coronary Artery Disease","Chronic Lung Diseases",[488],"Clinical Information System","2026-05-19",{"date":491,"type":44},"2026-05-27",{"date":382,"type":21},{"date":494,"type":21},"2027-12-31",{"name":50,"class":51},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":114,"sex":154,"minAge":504,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":52},"100637323","investigating-health-equity-and-resilience-in-girls-and-women-with-adhd-across-the-lifespan-100637323","NCT07597707","Investigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan","ADHD-Her: An Observational Research Protocol for Investigating Health, Equity, and Resilience (HER) in Girls and Women With ADHD Across the Lifespan","ADHD-Her","Inclusion Criteria:\n\n* Assigned female at birth or identify as girl or women\n* Fluency in English or French\n* Aged 10 years or older\n* Currently reside in Canada\n* Access to technology to complete study measures\n\nExclusion Criteria:\n\n* Self-reported intellectual disability","10 Years",{"count":506,"type":21},1460,"The goal of this observational study is to generate a comprehensive, multi-dimensional dataset of health indicators collected from girls and women (aged 10 years and older) with and without ADHD across the lifespan. Participants will be asked to complete a detailed survey about hormonal and developmental life phases, ADHD status and symptoms, childhood experiences, health and well-being, and psychosocial outcomes.",[122],[122,256,510,511,512,513,514,515,516,517],"woman","girl","girls","female","females","hormone","hormones","hormonal","2026-05-13",{"date":489,"type":44},{"date":521,"type":44},"2025-08-25",{"date":523,"type":21},"2026-12-31",{"name":50,"class":51},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":533,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":542,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":557},"100456094","hyperhydration-in-children-with-shiga-toxin-producing-e-coli-infection-100456094","NCT05219110","Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection","Hyperhydration to Improve Kidney Outcomes in Children With Shiga Toxin-Producing E. Coli Infection: A Multinational Embedded Cluster Crossover Randomized Trial","HIKO-STEC","Inclusion Criteria:\n\nIn order to be eligible to participate in this study (i.e., to be enrolled in the relevant institutional clinical care pathway), an individual must meet all of the following criteria:\n\n1. Aged 9.0 months to \\\u003C21 years at the time of informed consent.\n2. Evidence of high-risk STEC infecting pathogen defined by any of the following:\n\n   1. Bloody diarrhea within the preceding 7 days\n\n      * Positive STEC culture OR\n      * Positive antigen\u002Fpolymerase chain reaction test for toxin\u002Fgene type not otherwise specified OR\n   2. Bloody or Non-bloody diarrhea within the preceding 7 days\n\n      •Presumptive diagnosis of HUS\n      * (meeting all 3 HUS criteria - anemia, thrombocytopenia, and renal insufficiency) OR\n   3. Non-bloody or no diarrhea\n\n      * Positive STEC culture for high-risk strain (i.e., O103, O104, O111, O113, O121, O145 or O157) OR\n      * Positive antigen\u002Fpolymerase chain reaction test Stx2 toxin\u002Fgene\n\nExclusion Criteria:\n\nAll individuals meeting any of the exclusion criteria at baseline will be excluded from study participation.\n\n1. Presence of Advanced HUS defined by:\n\n   1. Hematocrit \\\u003C30% AND\n   2. Platelet count \\\u003C150 x 103\u002Fmm3 AND\n   3. Creatinine \\> 2.0 mg\u002FdL (177 µmol\u002FL)\n\n      * The presence of only 1 or 2 of these criteria will not result in patient exclusion, regardless of how close the 3rd criterion is to meeting the exclusion criteria.\n2. Prior episode of HUS or diagnosis of atypical HUS.\n3. Chronic disease limiting fluid volumes administered (e.g. impaired renal, liver, or cardiac function, chronic lung disease).\n4. Evidence of anuria (i.e., no urine output for \\> 24 hours).\n5. Hypoxemia requiring oxygen therapy\n6. Hypertensive emergency\n7. Greater than or equal to 10 days since onset of diarrhea or if no diarrhea then the onset of other symptoms.\n8. Patients with known pregnancy\n9. Patients or caregivers with language barriers impairing appropriate conduct of the study protocol.","9 Months","21 Years",{"count":536,"type":21},1040,[24],"The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).",[540,541],"Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection","Hemolytic-Uremic Syndrome",[543,544,545,546,547,548,549],"Child","Hemolytic Uremic Syndrome","Shiga-Toxigenic Escherichia coli","Renal Replacement Therapy","Acute Kidney Injury","Ambulatory Care","Emergency Department",{"date":551,"type":44},"2026-05-18",{"date":553,"type":44},"2022-09-29",{"date":555,"type":21},"2028-08-31",{"name":50,"class":51},26,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":4},"100636598","phase-2-continuous-vs-bolus-neuromuscular-blockade-regimens-in-moderate-to-severe-hypoxemic-respiratory-failure-and-ards-cobra-100636598","NCT07567768","Continuous vs Bolus Neuromuscular Blockade Regimens in Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA)","The Effect of Continuous vs Bolus Neuromuscular Blockade Regimens for Patients With Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA): A Pilot Randomized Controlled Trial","COBRA","Inclusion Criteria:\n\nAge ≥18 years\n\n* Mechanically ventilated and on a controlled ventilation mode\n* Diagnosis of moderate to severe ARDS (PaO₂\u002FFiO₂ ≤150 mmHg on PEEP ≥5 cm H₂O)\n* Bilateral pulmonary infiltrates consistent with ARDS\n* Randomized within 24 hours of meeting ARDS criteria\n\nExclusion Criteria:\n\n* Pregnancy\n* Known allergy or contraindication to rocuronium\n* Neuromuscular disorders (e.g., myasthenia gravis, Guillain-Barré syndrome)\n* Brain death or decision for withdrawal of life-sustaining therapy\n* Enrollment in a conflicting interventional trial",{"count":89,"type":21},[119],"Current clinical guidelines, such as those from the Surviving Sepsis Campaign and ARDSNet, recommend short-term NMBA use for patients with moderate to severe ARDS who exhibit persistent ventilator dyssynchrony or high plateau pressures despite deep sedation . However, they do not provide clear recommendations regarding the mode of administration. As a result, clinicians are left to extrapolate from limited or indirect evidence, which may lead to practice variation, uncertainty, and suboptimal care.\n\nThis pilot randomized controlled trial is designed to directly address this critical gap by comparing intermittent bolus administration versus continuous infusion of NMBAs in a pragmatic, real-world ICU setting. The study will assess feasibility metrics necessary to plan a definitive trial and generate preliminary clinical data on safety and effectiveness. By clarifying the comparative benefits and risks of each approach, the results may influence practice guidelines, reduce variation in care, and improve patient outcomes and reduce practice variation.patient outcomes, optimize resource use, and inform future guidelines on the management of moderate to severe ARDS.",[570],"ARDS (Acute Respiratory Distress Syndrome)",[572,573,574],"ARDS","Neuromuscular Blockade","mechanical ventilation","2026-05-11",{"date":577,"type":44},"2026-05-14",{"date":579,"type":21},"2027-01-01",{"date":581,"type":21},"2028-01-01",{"name":50,"class":51},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":605},"100586864","feasibility-and-pilot-testing-of-my-heart-and-ckd-online-shared-decision-aid-100586864","NCT06920927","Feasibility and Pilot Testing of \"My Heart and CKD\" Online Shared Decision Aid","Feasibility and Pilot Testing of the \"My Heart and CKD\" Online Shared Decision Aid","MyHeart&CKD","Inclusion Criteria:\n\n* Adult (18 years of age or older)\n* Chronic kidney disease\n* Coronary artery disease (non-ST elevation acute coronary syndrome (ACS) or symptoms or signs of stable coronary heart disease)\n* Able to communicate in English or French or through a support person who speaks English or French\n* Patient has the cognitive ability or has a surrogate decision maker capable of participating in shared decision making based on the discretion of the attending physician\n\nExclusion Criteria:\n\n* End stage kidney failure already being treated with dialysis or with an eGFR \\\u003C 10mL\u002Fmin\u002F1.73m2\n* ST-elevation myocardial infarction\n* Patient is not expected to survive to hospital discharge",{"count":592,"type":21},220,[24],"Many people with kidney disease also have heart disease. The procedures used to diagnose and treat heart disease (e.g., angiograms, angioplasty, or surgery) can improve symptoms and cardiovascular outcomes, but pose greater risks of kidney complications for people with chronic kidney disease. It's therefore important that patients with kidney disease and their health care providers understand the benefits versus risks of these procedures and use that information to make informed decisions regarding their health care.\n\nPrior research done with patients with kidney disease and their health care providers has led to the develop of a decision aid designed to help doctors provide personalized information on the benefits versus risks of having a heart procedure, as well as help patients communicate their own values and preferences to their doctor. This information is crucial for shared decision making, as previous research has shown that preferences and values vary for individual patients with kidney diseases, and should be incorporated into the decision-making process for heart disease management. The decision aid, called \"My Heart Care and CKD\", supports shared decision-making between patients with kidney disease and heart their care providers. This trial will implement and evaluate this decision aid within cardiovascular care in a pilot trial in Canada.",[596,485],"Chronic Kidney Disease",[598,599],"Decision aid","Shared decision making",{"date":577,"type":44},{"date":602,"type":44},"2025-12-01",{"date":494,"type":21},{"name":50,"class":51},2,{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":620,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":626,"leadSponsor":628,"locationsCount":605},"100584181","phase-2-psilocybin-assisted-therapy-for-post-traumatic-stress-disorder-in-survivors-of-intimate-partner-violence-100584181","NCT06885996","Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","PsiPTSD","Inclusion Criteria:\n\n* Individuals of all sexes, gender identities, and ethnicities\n* Ages 19 to 65 years at the time of screening\n* At least 6 months since last IPV incident\n* A score of 1 on the Composite Abuse Scale with repetition of abusive events\n* Minimum PCL-5 score of ≥ 33\n* Limited lifetime use of serotonergic hallucinogens\n* Ability to read\u002Fwrite English\n\nExclusion Criteria:\n\n* Severe or moderate substance use disorder other than nicotine in past 6 months\n* Lifetime diagnosis of schizophrenia or bipolar disorders (or first or second-degree relative)\n* Active suicidal ideation or serious attempt within the past 1 year.\n* Current pregnancy or nursing, trying to become pregnant\n* Any notable abnormality on ECG or routine medical blood laboratory test\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia\n* Epilepsy with a history of seizures\n* Current or recent (within 12 weeks) participation in a clinical trial\n* Cognitive impairment (SLUMS score \\\u003C20)\n* Suffered a moderate\u002Fsevere TBI at least once in lifetime\n* Suffered a mild TBI within the last 6 months\n* Any other circumstances that, in the opinion of the investigators, compromises participant safety\n* Not compelled to enter treatment to avoid legal consequences",{"count":614,"type":21},76,[119],"The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTSD) symptom burden in adult (aged 18-65) survivors of intimate partner violence (IPV).\n\nThis trail will test the following 2 aims:\n\nAIM 1 : To compare the efficacy of a therapeutic psilocybin dose at improving outcomes on the PCL-5 and CAPS-5 as compared to an active control psilocybin dose in IPV survivors with chronic PTSD.\n\nAIM 2: To evaluate the efficacy of psilocybin on quality of life, cognitive function, motor ability, depression, anxiety, and cognitive flexibility.\n\nParticipants will be asked to:\n\n* Complete a 2 part screening process\n* Attend a baseline assessment\n* Complete a psychoeducation preparation session(s)\n* Attend psilocybin administration session (receive high dose \\[25mg\\] or low dose psilocybin \\[1mg\\])\n* Complete 5-6 weekly sessions of ACT\n* Repeat outcome measures at 1-week, 4 weeks, 3 months (online questionnaires only), and 6 months post-psilocybin administration.",[618,619],"Post Traumatic Stress Disorder PTSD","Intimate Partner Violence (IPV)",[621,622,623],"Psychotherapy","Psilocybin","Acceptance and Commitment Therapy",{"date":577,"type":44},{"date":204,"type":21},{"date":627,"type":21},"2029-08-01",{"name":50,"class":51},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":639,"briefSummary":640,"conditions":641,"keywords":4,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":605},"100557387","uptake---virtual-care-virtual-home-hospital-with-remote-monitoring-to-reduce-acute-care-hospitalization-100557387","NCT06537453","UPTAKE - Virtual Care: Virtual Home Hospital With Remote Monitoring to Reduce Acute Care Hospitalization","Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events - Virtual Care: Virtual Home Hospital With Remote Monitoring to Reduce Acute Care Hospitalization","UPTAKE-VC","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.\n* Hospitalization \\> 48 hours.\n* LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.\n* Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.\n\nExclusion Criteria:\n\n* Non-Alberta residents.\n* Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.\n* C1 or C2 goals of care.\n* Hospitalization \\> 30 days.\n* Will be discharged to long-term care.\n* Kidney failure receiving dialysis.\n* Already admitted in Virtual Home Hospital Program",{"count":638,"type":21},354,[24],"Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death\n\nStudy Intervention: Multi-component Digital Health Solutions, including:\n\n1. Computerized Clinical Decision Support (CDS) and\n2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression",[547],{"date":577,"type":44},{"date":644,"type":44},"2024-08-10",{"date":646,"type":21},"2026-10-31",{"name":50,"class":51},{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":114,"sex":17,"minAge":655,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":22,"phases":658,"briefSummary":659,"conditions":660,"keywords":663,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":670,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":605},"100528721","implementing-individualized-patient-reported-outcome-measures-in-routine-care-of-patients-with-coronary-artery-disease-100528721","NCT06164457","Implementing Individualized Patient Reported Outcome Measures in Routine Care of Patients With Coronary Artery Disease","Implementing Individualized Patient Reported Outcome Measures in Routine Care of Patients With Coronary Artery Disease: a Pilot Study","Patient Inclusion Criteria:\n\n* age at least 40 years.\n* either (i) known coronary artery disease (defined as a history of myocardial infarction, percutaneous or surgical coronary revascularization, or documentation of obstructive coronary artery disease on previous invasive or CT angiography) or (ii) suspected coronary artery disease (defined as stable angina or anginal equivalent symptoms) as the reason for referral to a cardiologist.\n* Able to communicate in English or be willing to have an English-speaking family member or friend assist with survey completion.\n* Access to the internet, valid email address, and a web-enabled device, for survey completion.\n* Upcoming outpatient visit with a study cardiologist in the next 14-28 day\n\nExclusion criteria:\n\n\\- N\u002FA, all inclusion criteria must be met to participate\n\nPhysician Inclusion Criteria: We will recruit 4 cardiologists to participate, 2 each from Alberta Health Services Edmonton and Calgary zones, including both academic and community practice settings. To be eligible, cardiologists will need to have an active outpatient practice including moderate to high volumes of patients being assessed and managed for coronary artery disease, and to be willing to commit to participating in all aspects of the study","40 Years",{"count":657,"type":21},200,[24],"Investigators recently developed the APPROACH electronic patient reported outcome (ePROM) Survey and Clinician Report tools to collect individual results from online quality of life and health status surveys for patients with coronary heart disease, and report them back to their treating clinicians. This pilot interventional study uses a pre-post design to assess whether implementing the ePROM system into routine care is feasible and acceptable to patients and physicians, and to inform feasibility for a larger clinical trial. Specifically, the investigators aim to evaluate use of the ePROM Patient Survey and Clinician Report among eligible outpatients with known or suspected coronary artery disease and their cardiologists. Additionally, the investigators aim to determine if the use of the APPROACH ePROMs Clinician Report in routine medical encounters is acceptable (based on administrative burden, ease of use, and time required) to patients and clinicians, and supports effective communication for management of symptoms of coronary artery disease.",[485,661,662],"Patient Acceptance of Health Care","Physician-Patient Relations",[664,665,666,667,668,669],"coronary artery disease","patient reported outcome measures","cardiac science","communication assessment","quality improvement","feasibility",{"date":577,"type":44},{"date":672,"type":44},"2024-06-08",{"date":674,"type":21},"2027-09",{"name":50,"class":51},{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":680,"acronym":681,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":17,"minAge":683,"maxAge":684,"enrollmentInfo":685,"targetDuration":4,"studyType":22,"phases":686,"briefSummary":687,"conditions":688,"keywords":690,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":693,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":697,"locationsCount":52},"100403353","finding-alternatives-to-standard-treatment-for-attention-deficit-hyperactivity-disorder-100403353","NCT04532190","Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder","FAST-ADHD","Inclusion Criteria:\n\n1. Diagnosis of ADHD\n2. 9-15 years old\n3. IQ greater than 80\n4. English fluency (to enable consent\u002Fassent)\n5. If on medication, must have been on the same type and dosage for at least 3 months.\n\nExclusion Criteria:\n\n1. Diagnosis of mania, psychosis, or bipolar disorder\n2. Impediments to TMS or MRI (i.e. metal implants in body)\n3. Prior electroconvulsive therapy or vagus nerve stimulation\n4. Diagnosis of Autism Spectrum Disorder.","9 Years","15 Years",{"count":62,"type":21},[24],"Attention-Deficit\u002FHyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.",[689],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[691,692],"Attention-Deficit\u002FHyperactivity Disorder (ADHD","Repetitive transcranial magnetic stimulation (rTMS)",{"date":577,"type":44},{"date":695,"type":44},"2026-03-01",{"date":494,"type":21},{"name":50,"class":51},""]